The FDA has awarded a fast-track designation to Astellas’ peanut allergy vaccine candidate.
With €5 million in government funding, Themis and European collaborators have teamed up to create the newest Zika vaccine partnership.
The WHO estimates the average medication adherence rate is 50% in developed nations, though the U.S. trails other countries in reported adherence on Medisafe.…
Valneva is set to advance its Lyme disease vaccine candidate into clinical testing on both sides of the Atlantic.
The CDC has signed a $911 million contract to stockpile Emergent BioSolutions' BioThrax.
Tech billionaire Sean Parker’s startup Parker Institute for Cancer Immunotherapy has paired with the legacy Cancer Research Institute to advance development of…
A recently accepted study revived claims that vaccines can cause autism, but, after heavy criticism of the research, the online journal retracted the abstract.
Bavarian Nordic is closer to the finish line in the U.S. with its smallpox vaccine Imvamune.
Themis closed a second round of financing worth €10 million, which will be used for its Chikungunya vaccine and to further a Zika-fighting candidate.
A team of scientists from Australia is making progress in developing a vaccine that protects the human “surfaces” most likely to encounter the virus first.
Though cancer vaccines have experienced disappointing clinical performance in recent years, their global market as a crucial tool in immunotherapy will grow to…